PAVmed Inc. (PAVM): Nasdaq/NYSE listing notice — PAVmed receives Nasdaq minimum bid price deficiency notice; sells Series C preferred shares

PAVmed Inc.

Nasdaq notice on Jan 23: common stock closing bid below $1 for 30 consecutive days; 180-day cure period until July 22, 2025.
To regain compliance, closing bid must be at least $1 for 10 consecutive business days.
On Jan 24, sold 2,653 Series C Convertible Preferred shares for ~$2.653M via cancellation of unsecured debt.
Conversion at voluntary price $1.068/share would issue ~2.48M common shares; at floor $0.2136, ~12.42M shares.
Company intends to consider all available options to regain compliance with Nasdaq listing standards.

item 3.01 item 3.02 item 3.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through January 22, 2025), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until July 22, 2025) to regain compliance. In order to regain compliance, the closin

View on SEC.gov

Browse all listing & compliance notices →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-003631

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.